4.7 Review

An appraisal of genetic testing for prostate cancer susceptibility

期刊

NPJ PRECISION ONCOLOGY
卷 6, 期 1, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41698-022-00282-8

关键词

-

类别

资金

  1. Peter Gilgan Center for Women's Cancers
  2. Women's College Research Institute

向作者/读者索取更多资源

Most criteria for genetic testing for prostate cancer susceptibility require a prior diagnosis of prostate cancer, but advances in the field may improve outcomes and offer screening and prevention for high-risk individuals. Understanding the value of genetic testing and the impact of germline pathogenic variants on treatment for different stages of prostate cancer is important.
Most criteria for genetic testing for prostate cancer susceptibility require a prior diagnosis of prostate cancer, in particular cases with metastatic disease are selected. Advances in the field are expected to improve outcomes through tailored treatments for men with advanced prostate cancer with germline pathogenic variants, although these are not currently offered in the curative setting. A better understanding of the value of genetic testing for prostate cancer susceptibility in screening, for early detection and prevention is necessary. We review and summarize the literature describing germline pathogenic variants in genes associated with increased prostate cancer risk and aggressivity. Important questions include: what is our ability to screen for and prevent prostate cancer in a man with a germline pathogenic variant and how does knowledge of a germline pathogenic variant influence treatment of men with nonmetastatic disease, with hormone-resistant disease and with metastatic disease? The frequency of germline pathogenic variants in prostate cancer is well described, according to personal and family history of cancer and by stage and grade of disease. The role of these genes in aggressive prostate cancer is also discussed. It is timely to consider whether or not genetic testing should be offered to all men with prostate cancer. The goals of testing are to facilitate screening for early cancers in unaffected high-risk men and to prevent advanced disease in men with cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据